malaria in Africa

malaria in Africa
Name	Malaria in Africa
Field	Infectious disease

malaria in Africa Malaria in Africa is a major public health challenge across sub-Saharan regions and some North African locales, driven by ecological, demographic, and health-system factors. The disease imposes high morbidity and mortality, influencing development, urbanization, and cross-border mobility across the continent.

Epidemiology and Burden

Malaria incidence and mortality vary across countries such as Nigeria, Democratic Republic of the Congo, Uganda, Mozambique, Tanzania, Ghana, Kenya, Ethiopia, Senegal, Cameroon, Côte d'Ivoire, Mali, Burkina Faso, Niger, Angola, Zambia, Zimbabwe, Madagascar, South Africa, Botswana, Namibia', Sudan, South Sudan, Rwanda, Burundi, Sierra Leone, Liberia, Gabon, Equatorial Guinea, Chad, Central African Republic, Benin, Togo, Guinea, Guinea-Bissau, Mauritania, Cape Verde, Comoros, Sao Tome and Principe, Lesotho, Swaziland, Mauritius, Algeria, Tunisia, Morocco and Egypt; international burden estimates are provided by World Health Organization and modeled by groups including Institute for Health Metrics and Evaluation and Malaria Atlas Project. Large outbreaks have historical precedents linked to events such as the construction of railways and colonial-era projects like those in Kenya and Zimbabwe; contemporary spikes correlate with humanitarian crises in Darfur, Somalia and displacement from conflicts like in Libya and Mali. Vulnerable populations include children under five in Sierra Leone and pregnant women in Nigeria; socioeconomic impacts affect sectors in Ghana and Ethiopia while international donors such as the Global Fund and Bill & Melinda Gates Foundation allocate funding alongside bilateral programs like President's Malaria Initiative.

Causes and Transmission

Malaria in Africa is primarily caused by the parasite Plasmodium falciparum with contributions from Plasmodium vivax in parts of Horn of Africa and Sahel zones; transmission is mediated by vectors in the Anopheles genus, notably species complexes such as Anopheles gambiae complex and Anopheles funestus complex. Environmental drivers include climate variability linked to phenomena like El Niño–Southern Oscillation and land-use changes from projects such as irrigation schemes in Nile Delta and mining in Democratic Republic of the Congo. Human mobility across corridors like the Trans-Sahara Highway and maritime routes linking West Africa to Europe influences parasite importation; historical movements during events like the Atlantic slave trade altered parasite distributions. Vector ecology is influenced by urbanization in Lagos and Kinshasa, deforestation near Mwanza and agricultural practices in Senegal River Valley.

Clinical Presentation and Diagnosis

Patients present with febrile illness resembling syndromes seen in settings like Kampala and Lusaka: fever, chills, anemia, respiratory distress and cerebral manifestations especially in children in Kigali and Freetown. Severe disease sequelae include cerebral malaria documented in case series from Malawi and Zambia, and placental malaria described in cohorts from Accra and Dar es Salaam. Diagnostic strategies employ microscopy used in laboratories at institutions such as Makerere University and University of Cape Town, rapid diagnostic tests procured by programs in Rwanda and Botswana, and polymerase chain reaction techniques developed by research centers like Wellcome Trust–funded units and the Noguchi Memorial Institute for Medical Research. Differential diagnoses in clinic settings include bacterial sepsis seen in Sierra Leone or viral infections reported in Guinea.

Treatment and Drug Resistance

First-line treatments across many national guidelines in Kenya, Uganda, Ghana and Tanzania rely on artemisinin-based combination therapies endorsed by World Health Organization and procured via mechanisms involving Global Fund and UNICEF. Resistance concerns trace to reduced artemisinin sensitivity observed in surveillance networks linking research from MalariaGEN, Institut Pasteur, and national reference labs in Senegal and South Africa; partner organizations such as Centers for Disease Control and Prevention and PATH support molecular monitoring. Historical drug resistance to chloroquine and sulfadoxine–pyrimethamine reshaped policies after evidence from trials at sites like Ifakara Health Institute and Kenya Medical Research Institute. Adjunctive management includes intravenous artesunate and supportive care available in tertiary centers such as Mulago Hospital and Chris Hani Baragwanath Hospital.

Prevention and Control Measures

Core prevention measures include insecticide-treated nets distributed via campaigns coordinated by UNICEF, mass distribution supported by Global Fund, and indoor residual spraying applied in programs run by ministries of health in Mozambique and Malawi. Larval source management has been implemented in pilot projects in The Gambia and urban vector control trials in Dar es Salaam; environmental management projects have links to initiatives by World Bank and African Development Bank. Intermittent preventive treatment in pregnancy is delivered through antenatal platforms in clinics affiliated with Jhpiego and Marie Stopes International; seasonal malaria chemoprevention is adopted in Sahelian countries including Mali, Niger and Burkina Faso following WHO guidance. Cross-border elimination efforts involve regional bodies like African Union and Economic Community of West African States.

Public Health Infrastructure and Policy

National malaria control programs operate within health systems managed by ministries such as the Ministry of Health (Kenya) and Ministry of Health (Nigeria), with surveillance bolstered by integrated disease surveillance initiatives supported by World Health Organization regional offices and training collaborations with universities such as University of Nairobi and Makerere University. Financing mixes domestic budgets exemplified by South Africa with external assistance from Global Fund, Gavi, the Vaccine Alliance, and bilateral donors including United States Agency for International Development. Policy challenges intersect with supply chains coordinated by Supply Chain Management System partners and regulatory oversight by agencies like South African Health Products Regulatory Authority and National Agency for Food and Drug Administration and Control in Nigeria.

Research, Vaccines, and Innovations

Vaccine development milestones include deployment of vaccines such as those trialed at Kenya Medical Research Institute sites and evaluated under programs by PATH Malaria Vaccine Initiative; the Renewable candidates progressed through trials coordinated by institutions like Oxford University and London School of Hygiene & Tropical Medicine. Gene-drive vector control research involves collaborations among Target Malaria, Imperial College London and African partners; novel diagnostics and digital surveillance are piloted with technology partners in Rwanda and Ghana and modeled by Malaria Atlas Project and Institute for Health Metrics and Evaluation. Implementation research occurs in settings such as Ifakara and KEMRI–Wellcome Trust Research Programme to inform scale-up of innovations endorsed by World Health Organization and multilaterals such as UNICEF.

Category:Infectious diseases in Africa